Clinical trial
Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or…
NCT00092924 · Human Genome Sciences Inc., Industry · Completed
Key facts
| NCT number | NCT00092924 |
|---|---|
| Title | Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Phase 2, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of TRM-1 (Fully Human Monoclonal Antibody To TRAIL-R1) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer |
| Lead sponsor | Human Genome Sciences Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | TRAIL-R1 mAb (TRM-1, HGS-ETR1) |
| Primary completion | Jan 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Sep 28, 2004 |
| Last update posted | Aug 2, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: